# Fondation de Rothschild

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/fondation-de-rothschild/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 59.5 |
| Citations | 199,918 |
| City | Paris |
| Country | FR |
| Description | Fondation de Rothschild is a research organisation in Paris, FR. OpenAlex records 3,614 works and 199,918 citations for it. 1,054 researchers list it as their most recent affiliation. |
| Homepage | http://www.fondation-de-rothschild.fr/ |
| OpenAlex ID | https://openalex.org/I4210127304 |
| Researchers | 1,054 |
| ROR ID | https://ror.org/02yfw7119 |
| Type | nonprofit |
| Works | 3,614 |

## University papers

- [Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study](https://scholariq.org/papers/siponimod-versus-placebo-in-secondary-progressive-multiple-sclerosis-expand-a/)
- [Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults](https://scholariq.org/papers/clinical-spectrum-and-prognostic-value-of-cns-mog-autoimmunity-in-adults/)
- [Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis](https://scholariq.org/papers/clinical-characteristics-and-outcomes-in-patients-with-coronavirus-disease-2019/)
- [MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study](https://scholariq.org/papers/md1003-high-dose-biotin-for-the-treatment-of-progressive-multiple-sclerosis-a/)
- [Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease](https://scholariq.org/papers/clinical-features-and-risk-of-relapse-in-children-and-adults-with-myelin/)
- [Dynamic <scp>I</scp>maging of <scp>I</scp>ndividual <scp>R</scp>emyelination <scp>P</scp>rofiles in <scp>M</scp>ultiple <scp>S</scp>clerosis](https://scholariq.org/papers/dynamic-scp-i-scp-maging-of-scp-i-scp-ndividual-scp-r-scp-emyelination-scp-p-scp/)
- [High doses of biotin in chronic progressive multiple sclerosis: A pilot study](https://scholariq.org/papers/high-doses-of-biotin-in-chronic-progressive-multiple-sclerosis-a-pilot-study/)
- [Neuromyelitis optica in France](https://scholariq.org/papers/neuromyelitis-optica-in-france/)
- [Immunosuppressive therapy is more effective than interferon in neuromyelitis optica](https://scholariq.org/papers/immunosuppressive-therapy-is-more-effective-than-interferon-in-neuromyelitis/)
- [Aquaporin-4 antibody–negative neuromyelitis optica](https://scholariq.org/papers/aquaporin-4-antibody-negative-neuromyelitis-optica/)
- [Patterns of Objective and Subjective Burden of Informal Caregivers in Multiple Sclerosis](https://scholariq.org/papers/patterns-of-objective-and-subjective-burden-of-informal-caregivers-in-multiple/)

## University researchers

- [Caroline Papeix](https://scholariq.org/researchers/caroline-papeix/)

## University top topics

Showing 8 of 25.

- [Acute Ischemic Stroke Management](https://scholariq.org/topics/acute-ischemic-stroke-management/)
- [Intracranial Aneurysms: Treatment and Complications](https://scholariq.org/topics/intracranial-aneurysms-treatment-and-complications/)
- [Corneal surgery and disorders](https://scholariq.org/topics/corneal-surgery-and-disorders/)
- [Cerebrovascular and Carotid Artery Diseases](https://scholariq.org/topics/cerebrovascular-and-carotid-artery-diseases/)
- [Ophthalmology and Visual Impairment Studies](https://scholariq.org/topics/ophthalmology-and-visual-impairment-studies/)
- [Glaucoma and retinal disorders](https://scholariq.org/topics/glaucoma-and-retinal-disorders/)
- [Retinal Diseases and Treatments](https://scholariq.org/topics/retinal-diseases-and-treatments/)
- [Vascular Malformations Diagnosis and Treatment](https://scholariq.org/topics/vascular-malformations-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.